ATE319830T1 - Mutanten von streptococcaltoxin c und verfahren zu deren anwendung - Google Patents

Mutanten von streptococcaltoxin c und verfahren zu deren anwendung

Info

Publication number
ATE319830T1
ATE319830T1 AT97949733T AT97949733T ATE319830T1 AT E319830 T1 ATE319830 T1 AT E319830T1 AT 97949733 T AT97949733 T AT 97949733T AT 97949733 T AT97949733 T AT 97949733T AT E319830 T1 ATE319830 T1 AT E319830T1
Authority
AT
Austria
Prior art keywords
spe
toxin
vaccine
toxins
wild type
Prior art date
Application number
AT97949733T
Other languages
English (en)
Inventor
Patrick M Schlievert
Douglas Ohlendorf
David T Mitchell
Pamala J Gahr
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Application granted granted Critical
Publication of ATE319830T1 publication Critical patent/ATE319830T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97949733T 1996-12-06 1997-12-05 Mutanten von streptococcaltoxin c und verfahren zu deren anwendung ATE319830T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3325196P 1996-12-06 1996-12-06

Publications (1)

Publication Number Publication Date
ATE319830T1 true ATE319830T1 (de) 2006-03-15

Family

ID=21869358

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97949733T ATE319830T1 (de) 1996-12-06 1997-12-05 Mutanten von streptococcaltoxin c und verfahren zu deren anwendung

Country Status (14)

Country Link
US (1) US6835818B2 (de)
EP (1) EP0946730B1 (de)
JP (1) JP2002513278A (de)
KR (1) KR100615836B1 (de)
CN (1) CN1148449C (de)
AT (1) ATE319830T1 (de)
AU (1) AU734597B2 (de)
BR (1) BR9713679A (de)
CA (1) CA2273824C (de)
DE (1) DE69735439T2 (de)
DK (1) DK0946730T3 (de)
ES (1) ES2260804T3 (de)
PT (1) PT946730E (de)
WO (1) WO1998024910A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US7087235B2 (en) * 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
US6872394B1 (en) 1997-12-02 2005-03-29 Idaho Research Foundation, Inc. Non-toxic immune stimulating enterotoxin compositions
US7491402B2 (en) 1998-12-24 2009-02-17 Auckland Uniservices Limited Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof
EP1349568B1 (de) * 2000-12-04 2009-09-16 Auckland Uniservices Limited Immunmodulatorische konstruktionen und ihre verwendung
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0227026D0 (en) * 2002-11-20 2002-12-24 Molecular Skincare Ltd Psoriasis diagnostics and therapeutics
US7299231B2 (en) * 2004-07-29 2007-11-20 International Business Machines Corporation Method and system of subsetting a cluster of servers
CN109195988B (zh) 2016-01-10 2023-12-01 尼奥克斯医疗有限公司 用于增强超抗原介导的癌症免疫疗法效力的方法和组合物
SG11202011348YA (en) * 2018-05-16 2020-12-30 Univ Griffith Streptococcal toxic shock syndrome
WO2020230142A1 (en) 2019-05-15 2020-11-19 Neotx Therapeutics Ltd. Cancer treatment
WO2022074464A2 (en) 2020-03-05 2022-04-14 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784948A (en) 1983-08-10 1988-11-15 The Rockefeller University Production of streptococcal m protein immunogens and molecular probes
US5336598A (en) * 1989-11-15 1994-08-09 National Jewish Center For Immunology And Respiratory Medicine Method for diagnosing a superantigen caused pathologial condition via assay of T-cells
US5298396A (en) * 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
EP0626805A4 (en) 1992-01-28 1995-12-06 Nat Jewish Ct Immun & Respirat Protective effects of mutated superantigens.
US5460813A (en) * 1993-04-05 1995-10-24 National Jewish Center For Immunology And Respiratory Medicine Method for treating Kawasaki syndrome by administration of an anti-TSST-1 agent which is not gamma globulin
ES2239332T3 (es) 1995-06-07 2005-09-16 Regents Of The University Of Minnesota Mutantes de la toxina de estreptococos a y procedimientos de uso.

Also Published As

Publication number Publication date
HK1024265A1 (en) 2000-10-05
DE69735439D1 (de) 2006-05-04
AU734597B2 (en) 2001-06-21
JP2002513278A (ja) 2002-05-08
CN1240001A (zh) 1999-12-29
CA2273824A1 (en) 1998-06-11
US20020039585A1 (en) 2002-04-04
WO1998024910A2 (en) 1998-06-11
CA2273824C (en) 2007-05-08
BR9713679A (pt) 2001-07-17
DK0946730T3 (da) 2006-07-10
ES2260804T3 (es) 2006-11-01
DE69735439T2 (de) 2006-09-07
WO1998024910A3 (en) 1998-09-03
EP0946730A2 (de) 1999-10-06
US6835818B2 (en) 2004-12-28
KR20000069337A (ko) 2000-11-25
PT946730E (pt) 2006-06-30
KR100615836B1 (ko) 2006-08-25
EP0946730B1 (de) 2006-03-08
CN1148449C (zh) 2004-05-05
AU7625698A (en) 1998-06-29

Similar Documents

Publication Publication Date Title
ATE291625T1 (de) Streptococcus toxinmutanten und verfahren zu deren anwendung
DE60033530D1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
ATE513915T1 (de) Verbindungen und verfahren zur immuntherapie und diagnose von tuberkulose
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
AR001731A1 (es) Nueva celulasa método para producirla composición que la contiene vector que comprende al adn que lacodifica celula huesped método de aplicación
ATE319830T1 (de) Mutanten von streptococcaltoxin c und verfahren zu deren anwendung
ATE346860T1 (de) Mutanten von streptococcaltoxinen und vefahren zu deren anwendung
ES2164684T3 (es) Uso de antagonistas de taquiquininas en el tratamiento de emesis.
ATE226947T1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1- dioxiden, zusammensetzung und deren verwendung
DE69732709D1 (de) Expressionsblockierung von virulenten faktoren in s. aureus
DE69940692D1 (de) Verwendung von immunogenen immunsuppressiven und/oder angiogenen proteinen die inaktiviert sind, verfahren zur deren herstellung, und verwendungen als pharmazeutikum oder impfstoff
WO1996018646A3 (en) Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
DE69838324D1 (de) Ph-sensitive liposomen und andere typen immunomodulatoren enthaltender gekapselter impfstoffe sowie herstellungs- und anwendungsverfahren dafür
ATE103979T1 (de) Menschliches lymphotoxin.
ATE186731T1 (de) Anomere fluorribosylamine
NZ335534A (en) Method of identifying potential pharmaceuticals from plant extracts
DE69822870D1 (de) Verfahren zur desmethylierung von erythromycinen und deren derivaten
DE59611353D1 (de) Transketolase-verwandtes protein

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0946730

Country of ref document: EP

REN Ceased due to non-payment of the annual fee